Pfizer By The Numbers: 800 R&D Job Cuts But At Least Two Dozen Phase III Projects By Year End

Research chief Mackay says Pfizer's research portfolio has been extensively reviewed by both internal and outside experts

More from Archive

More from Pink Sheet